Research in contextEvidence before this studyThe mechanism of Mybbp1a in tumor initiation and progression was controversial. It was shown that Mybbp1a acted as a tumor suppressor in breast cancer by enhancing p53-associated anoikis and inhibiting the deacetylation activity of H3K18Ac. However, recent study demonstrated that Mybbp1a could enhance tumor cell proliferation in the early phase of HNSCC and inhibited tumor cell migration and invasion in advanced HNSCC. Moreover, the human protein atlas database showed that Mybbp1a may be favorable prognostic marker in pancreatic cancer, while unfavorable in renal cancer, thyroid cancer and melanoma. In addition, our study found that Mybbp1a was overexpressed in HCC tissues. Based on these, we propose that Mybbp1a may have a special function in the initiation and progression of HCC.Added value of this studyour study found that Mybbp1a suppressed the transcription of IGFBP5 through the DNMT1-mediated hyper-methylation level of CpG islands in the IGFBP5 CDS site. This biological process led to a loss of the secretion of IGFBP5, which improved the combinative efficiency between IGF1 and IGF1R. Then, phosphorylation of IGF1R induced the activation of the PI3K-AKT pathway, which increased the proliferation rate and migration capacity of HCC cells.Implications of all the available evidenceThese findings extend our understanding of the function of Mybbp1a in the progression of HCC. The newly identified Mybbp1a may provide a novel biomarker for developing potential therapeutic targets of HCC.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Hepatocellular carcinoma (HCC) is one of the most common solid tumors worldwide, and its incidence and mortality rate have persistently increased in recent years \[[@bb0005],[@bb0010]\]. Surgical resection and liver transplantation (LT) are first-line treatments in early HCC. However, many patients are diagnosed with advanced HCC and are not eligible for surgery \[[@bb0015],[@bb0020]\]. Furthermore, frequent metastasis and recurrence are the major reasons for the poor prognosis of HCC patients after surgical resection or LT \[[@bb0025]\]. Potential effective biomarkers for predicting the recurrence and prognosis of HCC are rare. Therefore, the identification of new molecular markers is needed.

MYB binding protein 1a (Mybbp1a) is a nucleolar transcriptional regulator that was first identified because of its ability to specifically bind to the MYB proto-oncogene protein \[[@bb0030], [@bb0035], [@bb0040]\]. Further studies proved that Mybbp1a also bind to several other transcription factors, including the RelA/p65 subunit of NF-kB, p53, PGC-1a and Prep1, and played an important role in many cellular processes, including the response to nucleolar stress, synthesis of ribosomal DNA and amino acids, and progression of the oxidative phosphorylation respiratory chain \[[@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080]\]. However, the function of Mybbp1a in solid tumors is controversial. A recent study proved that Mybbp1a acted as a tumor suppressor protein in breast cancer by enhancing p53-associated anoikis \[[@bb0085]\].Another study proved that Mybbp1a promoted tumor cell proliferation in the early phase of head and neck squamous cell carcinoma (HNSCC), while inactivation of MYBBP1A induced accelerated tumor cell migration and invasion in advanced tumors \[[@bb0090]\].Moreover, by integrating prognostic analysis from TCGA database, the human protein atlas database showed that Mybbp1a may be favorable prognostic marker in pancreatic cancer, while unfavorable in renal cancer, thyroid cancer and melanoma.

Thus, more studies are needed to determine the function of Mybbp1a in solid tumors. Here, we demonstrate Mybbp1a is overexpressed in HCC tissues and associated with poor prognosis of HCC patients. Additionally, Mybbp1a could promote the proliferation and migration of HCC cells by activating the IGF1/AKT pathway through inducing CpG-island methylation mediated IGFBP5 silencing.

2. Materials and methods {#s0025}
========================

2.1. Patients and specimens {#s0030}
---------------------------

This study was approved by the ethics committee of the First Affiliated Hospital of Zhejiang University, and informed consent was obtained from all patients. All cancer tissue samples and adjacent non-tumor tissue samples were obtained from 71 patients diagnosed with HCC during September 2012 to December 2013. Clinical data were collected from all these patients including age, gender, size of tumor, number of tumors, vessel invasion, tumor grade and AFP (alpha-fetoprotein). Follow-up information was obtained by reviewing the patient\'s medical records up to the termination date (January 31, 2016) or death.

2.2. Cell culture {#s0035}
-----------------

The HCC cell line SK-Hep-1 was purchased from the American Type Culture Collection (Manassas, VA). The liver cancer cell lines Huh7 and HCC-LM3 and the normal liver cell line QSG-7701 were purchased from the Chinese Academy of Science Cell Bank (Shanghai, China). All cell lines were proven by short tandem repeats (STR) and SNP fingerprinting before use. Cells were maintained in MEM or RPMI 1640 medium supplemented with 10% FBS at 37 °C in a humidified atmosphere of 5% CO~2~. The AKT inhibitor MK2206 was obtained from Selleck Chemicals (Houston, TX) and dissolved in ddH~2~O for the purpose of this research. IGF1 and IGFBP5 were obtained from Peprotech (Rocky Hill, USA) and dissolved in ddH~2~O with 3% BSA for research.

2.3. Construction of stably transfected cell lines {#s0040}
--------------------------------------------------

The target sequences of Mybbp1a (5′-GCUGGUGAAUGUGCUGAAGAUGGCC-3′),

and IGFBP5 (5′-CTCCCATTCTCCAATGACT-3′) were obtained from Shanghai Genechem Co., Ltd. and used to generate stable Mybbp1a or IGFBP5 knockdown cell lines according to the instructions of manufacturer. Cells were selected by puromycin (4 μg/ml) (Sangon, Shanghai, China) for 72 h, and the transfection efficiency was proved by quantifying EGFP fluorescence, RT-PCR and western blotting. Stably transfected Huh7 and HCC-LM3 cells were maintained in the Modified Eagle medium (MEM, Gibco, Grand Island, NY) containing 10% fetal bovine serum (FBS, Gibco) for further study.

2.4. Real-Time PCR and western blot {#s0045}
-----------------------------------

Real-Time PCR and western blot were conducted as previously descripted \[[@bb0095], [@bb0100], [@bb0105]\]. The primers were as follows: Mybbp1a, Forward 5′-GCATCCTGCAGCAGATACAA-3′, Reverse 5′-CAGCTTCACCGACTTCATCA-3′; IGFBP5, Forward 5′-TGACCGCAAAGGATTCTACAAG-3′, Reverse 5′-CGTCAACGTACTCCATGCCT-3′; and GAPDH, Forward 5′-GAATGGGGAAGGTGAAGGTCG-3′, Reverse 5′-GGGGTCATTGATGGCAACAATA-3′. The antibodies are shown in the Supplement Table 1.

2.5. Immunohistochemistry {#s0050}
-------------------------

Immunostaining (IHC) was performed on formalin-fixed, paraffin-embedded clinical tissue specimens. The expression levels of Mybbp1a in HCC tissues and neighbor tissues were detected as the previously descripted \[[@bb0095]\]. The IHC score was assessed by two independent investigators. The method for the IHC score was as follows: 0, negative; 1, \<25% positive tumor cells; 2, 25--50% positive tumor cells; 3, 50%--75% positive tumor cells; and 4, \>75% positive tumor cells. The intensity of the dye color was graded as 0 (no color), 1 (light yellow), 2 (light brown), or 3 (brown). The staining index was calculated as follows: staining index = staining intensity × tumor cell staining grade. High Mybbp1a expression levels were defined as a staining index score ≥ 6, while low expression was defined as a staining index \< 6.

2.6. Cell proliferation and migration experiments in vitro {#s0055}
----------------------------------------------------------

HCC cell lines with Mybbp1a knockdown, Mybbp1a + IGFBP5 knockdown or no knockdown (negative control) were used for cell proliferation and migration assays as previously described \[[@bb0100],[@bb0105]\].

2.7. Immunofluorescence staining {#s0060}
--------------------------------

The HCC Huh7-shMybbp1a, Huh7-NC, HCC-LM3-shMybbp1a and HCC-LM3-NC cells were fixed with 4% paraformaldehyde for 15 min and then permeabilized and simultaneously blocked with 0.1% Triton-X 100 and 1% BSA for 30 min. Cells were incubated sequentially with the Phalloidin-iFluor 647 conjugate (AAT Bioquest®, Inc., CA) for 1 h at room temperature and then with DAPI for 5 min. Finally, the cells were examined with a laser confocal microscope (FV1000, Olympus).

2.8. ELISA assay {#s0065}
----------------

The Human IGFBP-5 ELISA Kit was purchased from Ray Biotech, Inc. (ELH-IGFBP5-1, P24593), and the experiment was conducted according to the guidelines.

2.9. Tumor xenograft and lung metastasis {#s0070}
----------------------------------------

All experimental protocols were approved by the Animal Experimental Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine. The methods were carried out in accordance with the approved guidelines. Cells (5 × 10^6^) were resuspended in 100 μl of PBS and injected subcutaneously into the lateral flanks of immunodeficient mice. Tumor volumes were measured every three days and calculated using the following equation: V (cm^3^) = width2 (cm^2^) × length (cm)/2. The mice were sacrificed about five weeks after the injection. In addition, the nude mice were each injected via the tail vein with Mybbp1a-shRNA or Mybbp1a-NC (1 × 10^6^ cells). Mice were sacrificed 40 days after the tail vein injection, and the lungs were embedded in paraffin and sliced for HE staining to identify metastasis.

2.10. Expression microarrays {#s0075}
----------------------------

Huh7 cells were transfected with shMybbp1a and negative control respectively. After RNA preparation using RNeasy Protect Midi Kit (Qiagen, Valencia, CA), hybridization was conducted using Affymetrix whole-genome microarrays (hgu133Plus2) according to the manufacturer\'s instructions. Raw data were normalized using the RMA algorithm in R statistical computing environment ([www.r-project.org](http://www.r-project.org){#ir0005}) using the default parameters. The relative fold changes were calculated according to negative control.

2.11. Bisulfite sequencing and pyrosequencing {#s0080}
---------------------------------------------

Genomic DNA of cells was extracted using the standard phenol--chloroform technique followed by proteinase K treatment to prevent protein contamination. Bisulfite conversion was performed using an EpiTect Bisulfite Kit (QIAGEN) according to the manufacturer\'s instruction.The primers for IGFBP5 amplification were as follows: forward 5′-ATGTGTTTTTTTAGTTTTTTGGGTTG-3′; reverse 5′-ACAAAATCCTCCAAAACTCCAATT-3′.

For pyrosequencing, the amplified DNA products were detected by PyroMark Q96 ID (QIAGEN). The primers for IGFBP5 amplification were as follows: forward 5′-TTGGGTTGAGAGTTGGTTAAGGA-3′, reverse 5′-ACCCCAACTCCAAACCACTTACTAC-3′. The primer for sequencing was as follow: 5′-TGAGAGAGTTTAGTGTGTTAGTTAG-3′.

2.12. Co-immunoprecipitation {#s0085}
----------------------------

Co-immunoprecipitation was performed as previously described \[[@bb0110]\].

2.13. Chromatin Immunoprecipitations-PCR {#s0090}
----------------------------------------

Chromatin Immunoprecipitations-PCR was conducted by Shanghai Kangchen Bio-tech, and the IGFBP5 primers was showed in the Supplement Table 2.

2.14. Statistical analysis {#s0095}
--------------------------

Data are presented as the means ± standard deviation (SD). For comparisons, Student\'s *t*-test and Fisher\'s exact test were performed, as appropriate. Relapse-free -survival and overall-survival analysis were evaluated by the Kaplan-Meier method, and differences were assessed using the log-rank test. Cox multivariate regression analysis was used to identify independent prognostic factors. All analyses were performed with SPSS 18.0 software (SPSS Inc., Chicago, IL). Differences were considered significant at P \< .05.

3. Results {#s0100}
==========

3.1. Mybbp1a is overexpressed in HCC tissues and associated with a poor prognosis of HCC patients {#s0105}
-------------------------------------------------------------------------------------------------

To investigate the clinical significance of Mybbp1a expression, we measured its expression in 71 paired HCC tissues and adjacent non-tumor tissues. Immunohistochemical (IHC) assays showed that the average expression level of Mybbp1a was significantly higher in HCC tissues than that in adjacent non-tumor tissues ([Fig. 1](#f0005){ref-type="fig"}a). We also observed that the expression of Mybbp1a was higher in HCC cell lines (SK-Hep-1, Huh7, HCC-LM3) than that in normal liver cells (QSG-7701) ([Fig. 1](#f0005){ref-type="fig"}b). Kaplan-Meier analysis showed that higher expression of Mybbp1a was associated with shorter overall survival and tumor-free survival in HCC patients (P = .014 and P = .010, respectively) ([Fig. 1](#f0005){ref-type="fig"}c). This result was validated by liver cancer survival analysis in human protein atlas database ([www.proteinatlas.org](http://www.proteinatlas.org){#ir0010}) (Supplement Fig. 1). Cox multivariate regression analysis indicated that high expression of Mybbp1a was an independent and significant factor for overall and tumor-free survival (Supplement Table 2). Taken together, these data indicated that Mybbp1a was overexpressed in HCC and that its overexpression predicted a poor prognosis in HCC patients and might contribute to the progression of HCC.Fig. 1Mybbp1a was overexpressed in HCC tissues and associated with poor prognosis of HCC patients.(a) Showed the expression of Mybbp1a in HCC tissues and adjacent non-tumor tissues (200×, scale bar = 0.1 mm;400×, scale bar = 0.05 mm), and the results were quantified in the pie chart, (p \< .0001, student\'s *t*-test). (b) Showed the expression level of Mybbp1a in HCC cell lines and normal liver cells, (\*\*p \< .005, \*\*\*p \< .0005, student\'s *t*-test). (c) The overall and relapse-free survival of HCC patients between Mybbp1a high-expression group and Mybbp1a low-expression group were analyzed by Kaplan-meier analysis, (p = .014 and p = .010 respectively, Log Rank (Mantel-Cox)).Fig. 1

3.2. Suppression of Mybbp1a inhibits the proliferation of HCC cells via G1/S transition {#s0110}
---------------------------------------------------------------------------------------

According to the expression level of Mybbp1a in HCC cell lines, we stably transfected Mybbp1a-shRNA into the Huh7 and HCC-LM3 cell lines, and the transfection efficiency was proven at both the protein and mRNA levels ([Fig. 2](#f0010){ref-type="fig"}a). Loss of function experiments showed that suppression of Mybbp1a led to lower cell viability and a lower proliferation rate in both Huh7 and HCC-LM3 cells ([Supplement Fig. 2](#f0050){ref-type="graphic"}, [Fig. 2](#f0010){ref-type="fig"}b). Consistently, tumor formation assays showed that suppression of Mybbp1a significantly inhibited the tumorigenesis of HCC cells both in vitro and in vivo ([Fig. 2](#f0010){ref-type="fig"}c--d, [Supplement Fig. 3](#f0055){ref-type="graphic"}). Flow cytometry analysis revealed that knockdown of Mybbp1a induced G1 phase arrest ([Fig. 2](#f0010){ref-type="fig"}e, [Supplement Fig. 4](#f0060){ref-type="graphic"}). We also detected several G1 phase-associated proteins and discovered that suppression of Mybbp1a induced lower expression of CDK2, cyclin A2, CDK4 and cyclin E1, but higher expression of p21 ([Fig. 2](#f0010){ref-type="fig"}f, [Supplement Fig. 5](#f0065){ref-type="graphic"}). These results indicated that Mybbp1a played an important role in the proliferation and regulation of HCC cells.

3.3. Suppression of Mybbp1a inhibits the migration ability of HCC cells in vitro and in vivo {#s0115}
--------------------------------------------------------------------------------------------

Next, we evaluated whether Mybbp1a played a role in the motility of HCC cells. The results of transwell and wound-healing assays showed that suppression of Mybbp1a led to a lower migration ability than that of the negative control ([Fig. 3](#f0015){ref-type="fig"}a-b, [Supplement Fig. 6](#f0070){ref-type="graphic"}). Consistently, a pulmonary metastasis model showed that the Huh7-shNC group displayed more lung metastasis foci and larger metastatic tumors than those of the Huh7-shMybbp1a group ([Fig. 3](#f0015){ref-type="fig"}c). Then, we used phalloidin to observe the cell cytoskeleton in HCC cells and found that the numbers of microfilaments and microtubules were lower in the Huh7-shMybbp1a group than those in the negative control. Meanwhile, we observed that CDC42, which is an important molecule in cell cytoskeleton regulation, significantly decreased under the conditions of Mybbp1a suppression ([Fig. 3](#f0015){ref-type="fig"}d). These findings showed that Mybbp1a depletion may inhibit cell migration by regulating CDC42-associated cell cytoskeleton synthesis.

3.4. Mybbp1a promotes the proliferation and migration of HCC cells via PI3K/AKT pathway {#s0120}
---------------------------------------------------------------------------------------

To further explore the mechanism of Mybbp1a in regulating the proliferation and migration of HCC cells, we used Affymetrix whole-genome microarrays (hgu133Plus2) to investigate the differential genes and pathways between the Huh7-shMybbp1a and Huh7-NC groups. KEGG enrichment analysis showed that the PI3K/AKT signaling pathway was significantly changed among the classic biological regulatory pathways ([Fig. 4](#f0020){ref-type="fig"}a). Then, we detected the expression of pAKT^473^, pAKT^308^, PI3K-P110 and PI3K-P85 in Huh7 and HCC-LM3 cells and found that all of these molecules were significantly decreased under the condition of Mybbp1a suppression ([Fig. 4](#f0020){ref-type="fig"}b). To further demonstrate our findings, we used MK2206-2HCL (an inhibitor of AKT) to conduct a remedy experiment, and the inhibition efficiency was validated by western blot analysis ([Fig. 4](#f0020){ref-type="fig"}c). Then, we detected cell viability and migration ability in HCC-shMybbp1a and HCC-NC cells with or without 5 μmol/l MK2206-2HCL by the CCK-8 and transwell assays. The results showed that, except for the negative control (NC) group, the cell viability of the other groups was similar at 72 h ([Fig. 4](#f0020){ref-type="fig"}d). Consistently, this phenomenon also appeared in a cell migration experiment ([Fig. 4](#f0020){ref-type="fig"}e). In addition, we also demonstrated that inhibition of AKT activation induced a change in the expression of G1 phase-associated proteins and cytoskeletal synthesis reduction ([Supplementary Fig. 7](#f0075){ref-type="fig"}, [Supplementary Fig. 8](#f0080){ref-type="fig"}). Thus, our study proved that Mybbp1a regulated the proliferation and migration of HCC cells by promoting the activation of the PI3K/AKT signaling pathway.

3.5. IGFBP5 is negatively regulated by Mybbp1a in HCC cells {#s0125}
-----------------------------------------------------------

To further investigate the mechanism of Mybbp1a in the activation of the PI3K/AKT pathway, we analyzed the differential gene expression in our Affymetrix whole-genome microarrays. We found that IGFBP1, HAL, PPP2R2D, UCA1, WIF1, IGFBP5 and IGFBP2 had large fold changes under Mybbp1a suppression ([Fig. 5](#f0025){ref-type="fig"}a). A recent study proved that IGFBP5 was a potent inhibitor of both the signaling and functional outputs of IGF-1, which plays a vital role in the activation of the PI3K/AKT pathway \[[@bb0115]\]. Thus, we selected IGFBP5 for further study. First, we validated that IGFBP5 was significantly increased among the mRNA, intracellular protein and extracellular protein levels under Mybbp1a knockdown in Huh7 cells ([Fig. 5](#f0025){ref-type="fig"}b).Then, we analyzed patients with Mybbp1a^High^IGFBP5^Low^, Mybbp1a^Low^IGFBP5^High^, Mybbp1a^High^IGFBP5^High^ or Mybbp1a^Low^IGFBP5^Low^, the results showed that the overall and tumor-free survival of patients with Mybbp1a^High^IGFBP5^Low^ was shorter than those with Mybbp1a^Low^IGFBP5^High^ ([Fig. 5](#f0025){ref-type="fig"}c, [Supplement Fig. 9](#f0085){ref-type="graphic"}).In addition, we constructed three stably transfected cell lines, Huh7-shMybbp1a, Huh7-shMybbp1a + shIGFBP5 and a negative control, and the transfection efficiency was verified by western blotting ([Fig. 5](#f0025){ref-type="fig"}d). The CCK-8 assay showed that simultaneous knockdown of Mybbp1a and IGFBP5 reversed the decreased viability of cells induced by Mybbp1a knockdown alone ([Fig. 5](#f0025){ref-type="fig"}e). Consistently, the results of the transwell assay were similar to those of the cell viability experiment ([Fig. 5](#f0025){ref-type="fig"}f). Based on the above findings, we demonstrated that IGFBP5 was negatively regulated by Mybbp1a in HCC cells.

3.6. Mybbp1a promotes the activation of the IGF1/AKT signaling pathway by inhibiting the secretion of IGFBP5 {#s0130}
------------------------------------------------------------------------------------------------------------

The secretion of IGFBP5 inhibited the activation of IGF1R by competitive binding with IGF1 in the extracellular space \[[@bb0115]\]. Thus, we hypothesized that the inactivation of the PI3K-AKT pathway was mainly due to the inhibition of the IGF1 pathway in the case of Mybbp1a knockdown. We first validated that the phosphorylation of IGF1R and AKT by IGF1 (Peprotech, Product number 100-11) was inhibited after adding the recombinant protein IGFBP5 (Peprotech, Product number100-05) ([Fig. 6](#f0030){ref-type="fig"}a). Then, the CCK-8 assay showed that the cell viability of that IGF1 group was higher than that of IGFBP5 and IGF1 + IGFBP5 groups ([Fig. 6](#f0030){ref-type="fig"}b). Similarly, this phenomenon appeared in the cell migration experiment ([Fig. 6](#f0030){ref-type="fig"}c). Moreover, in comparison with no IGF1 treatment, we validated that the expression of pIGF1R and pAKT^473^ both increased under the condition of 40 ng/ml IGF1 in Huh7 cells with shMybbp1a, shMybbp1a + shIGFBP5 or a negative control. However, the expression of pIGF1R and pAKT473 in cells with shMybbp1a + shIGFBP5 and negative controls was higher than that of those with shMybbp1a ([Fig. 6](#f0030){ref-type="fig"}d). Taken together, these findings showed that suppression of Mybbp1a led to the inactivation of the IGF1/AKT pathway by inducing the secretion of IGFBP5.Fig. 2Suppression of Mybbp1a inhibited proliferation of HCC cells via G1/S transition. (a) The transfection efficiency of shMybbp1a and negative control (NC) in Huh7 and HCC-LM3 cells was verified both at protein and mRNA levels, (\*\*p \< .005, student\'s *t*-test). (b) The Edu assay was used to detect proliferation rate of HCC cells with shMybbp1a or negative control (NC), (scale bar = 10um) (\*\*\*p \< .0005, \*\*p \< .005, student\'s *t*-test). (c--d) The tumorigenic ability of Huh7-shMybbp1a and Huh7-NC was compared both in vitro and in vivo, (\*\*p \< .005, \*\*\*p \< .0005, student\'s *t*-test). (e) The cell cycle was detected by flow cytometry, and the results were analyzed by ModFIT software, (\*\*\*p \< .0005, \*\*p \< .005, student\'s *t*-test). (f) The expression of G1 phase associated proteins was detected by western blot, and β-actin was as the internal control.Fig. 2Fig. 3Suppression of Mybbp1a inhibited migration capacity of HCC cells. (a) Cell migration capacity was studied by transwell assay and the results were quantified, (\*\*p \< .005, student\'s *t*-test). (b)Showed the result of wound healing assay; the distance was evaluated with pictures taken at 0 h, 6 h, 24 h and 48 h, (\*\*p \< .005, \*p \< .05, student\'s *t*-test). (c) The lung metastasis experiment was conducted with Huh7-shMybbp1a and negative control (NC), the HE photos of metastatic tumor in lung were shown, and the number of metastatic nodes was quantified, (p = .0108, student\'s *t*-test). (d) The cytoskeleton of HCC cells with shMybbp1a and negative control (NC) under treatment of phalloidin was shown (scale bar = 1um), and CDC42 was detected by western blotting, and β-actin was as the internal control.Fig. 3Fig. 4Mybbp1a regulated proliferation and migration of HCC cells through PI3K/AKT pathway. (a) The number of differential genes in classic signaling pathways was showed. (b) The expression change of pAKT^473^, pAKT^308^, PI3K-P110 and PI3K-P85 in HCC cells was shown, and β-actin was as the internal control. (c) Expression of pAKT^473^and AKT were detected under different concentration of MK-2206 2HCL in HCC cells with shMybbp1a or negative control (NC). (d) Cell viability of HCC cells with shMybbp1a or negative control (NC) under different concentration of MK-2206 2HCL were shown, and the results of 72 h were used for statistical analysis,(\*p \< .05,one-way ANOVA). (e) Cell migration capacity of HCC cells with shMybbp1a or negative control (NC) under different concentration of MK-2206 2HCL were shown,(\*\*p \< .005, student\'s *t*-test).Fig. 4Fig. 5IGFBP5 was negatively regulated by Mybbp1a. (a) The differentially expressed genes from the transcriptome chip were shown. (b) The mRNA and protein levels of IGFBP5 between Huh7-shMybbp1a and Huh7-NC cells were detected, (\*\*P \< .005, \*\*\*p \< .0005, student\'s *t*-test). (c) Kaplan-meier analysis was used to compare prognosis between two group patients (our HCC cohort and TCGA HCC cohort), including Mybbp1a^high^IGFBP5^low^ and Mybbp1a^low^IGFBP5^high^ group, (p = .043,0.006 and 0.019 respectively, Log Rank (Mantel-Cox)) (d) Transfection efficiency of Huh7-shMybbp1a, Huh7-shMybbp1a + shIGFBP5 and Huh7-NC was verified by western blot. (e) Cell viability of HCC cells with shMybbp1a, shMybbp1a + shIGFBP5 or negative control (NC) was detected, and the results of 72 h were used for statistical analysis (\*\*p \< .005, one-way ANOVA). (f) Cell migration capacity of HCC cells with shMybbp1a, shMybbp1a + shIGFBP5 or negative control (NC) was detected, (\*p \< .05, \*\*p \< .005, student\'s *t*-test).Fig. 5Fig. 6Mybbp1a promoted activation of IGF1/IGF1R/PI3K/AKT through inhibiting secretion of IGFBP5. (a) The expression level of pAKT^473^, AKT, pIGF1R and pIGF1R were detected in Huh7 cells treated with IGF1 (40 ng/ml), IGF1 + IGFBP5 (40 ng/ml) or the control. (b) Cell viability of Huh7 cells treated with IGF1 (40 ng/ml), IGF1 + IGFBP5 (40 ng/ml) or the control was detected, and the results of 72 h were used for statistical analysis, (\*\*P \< .005, one-way ANOVA). (c) Cell migration capacity of Huh7 cells treated with IGF1 (40 ng/ml), IGF1 + IGFBP5 (40 ng/ml) or the control was detected, (\*\*p \< .005, student\'s *t*-test). (d) Expression level of pAKT^473^, AKT, pIGF1R and pIGF1R were detected after treatment with IGF1 0 ng/ml or 40 ng/ml. The results were quantified by Image J, (\*P \< .05, \*\*P \< .005 and \*\*\*P \< .0005, student\'s *t*-test).Fig. 6

3.7. Mybbp1a inhibits the transcription of IGFBP5 by promoting CpG island methylation {#s0135}
-------------------------------------------------------------------------------------

As the suppression of Mybbp1a significantly increased the mRNA level of IGFBP5, we sought to determine how Mybbp1a affected the expression of IGFBP5, through transcriptional level or post-transcriptional level. First, we conducted microRNA sequencing to search for candidate microRNA which affected expression of IGFBP5 in post-transcriptional level. Considering that the mRNA level of IGFBP5 was upregulated under suppression of Mybbp1a, we selected miRNAs that were decreased in the Huh7-shMybbp1a group. Based on the above findings, five miRNAs (miR-3187-3p, miR-210-5p, miR-671-5p, miR-1260b and miR-128-1-5p) were found ([Supplement Fig. 10](#f0090){ref-type="graphic"}a). However, there was no significant change in the IGFBP5 mRNA level under treatment with miRNA mimics in Huh7 cells ([Supplement Fig. 10](#f0090){ref-type="graphic"}b). Bioinformatics analysis (MethPrimer 2.0) showed that the CpG islands of IGFBP5 were not in the promoter site, while found one in the CDS (coding sequence) site ([Supplement Fig. 11](#f0095){ref-type="graphic"}).Then we found that the methylation of CDS CpG island of IGFBP5 in HCC tissues was higher than that in normal tissues, and mRNA level of IGFBP5 was negative correlated with methylation level of CDS CpG island of IGFBP5 in HCC patients with Mybbp1a^high^IGFBP5^low^ ([Fig. 7](#f0035){ref-type="fig"}a), we thought that Mybbp1a may regulate the mRNA level of IGFBP5 at the transcriptional level through CpG island methylation. By analyzing the methylation level of 40 CpGs in the IGFBP5 CDS site through Bisulfite Sequencing PCR, we observed that the CpG methylation level of the negative control was higher than that of the shMybbp1a group, ranging from 26 CpG to 36 CpG. Then, we quantified the methylation percentage of these 11 CpGs (+259--+310) by pyrosequencing. The results showed that the methylation levels at position 1, 4, 5, 7, and 10 were significantly decreased under Mybbp1a suppression ([Fig. 7](#f0035){ref-type="fig"}b). As the results of Bisulfite Sequencing PCR showed that the methylation levels of position 7--11 were significantly different between the NC group and shMybbp1a group in HCC cell lines ([Fig. 7](#f0035){ref-type="fig"}c); thus, we selected these five CpG sites for further study. Then, we used Azacitidine (5Aza) to treat the HCC cell lines, and the results of Bisulfite Sequencing PCR showed that the methylation levels of position 7--11 were decreased ([Fig. 7](#f0035){ref-type="fig"}d). In addition, we found that the mRNA level of IGFBP5 was significantly increased after treatment with 5Aza (0, 10, 20, 40 μmol/l) ([Fig. 7](#f0035){ref-type="fig"}e). The inhibition efficiency of 5Aza was verified by detecting the expression of DNMT1 under different concentrations of 5Aza ([Fig. 7](#f0035){ref-type="fig"}f). Therefore, our study demonstrated that Mybbp1a inhibited the transcription of IGFBP5 by promoting the methylation of CpG islands in the CDS site.

3.8. Mybbp1a promotes the methylation of CpG islands of IGFBP5 through DNMT1 {#s0140}
----------------------------------------------------------------------------

To demonstrate the mechanism of Mybbp1a\'s regulation of the methylation of CpG islands of IGFBP5, we conducted Chip-PCR analysis to determine whether Mybbp1a and DNMT1 could combine with the CDS site of IGFBP5. We designed 6 primers according to the CDS site of IGFBP5, and the results showed that all of the primers had PCR products ([Fig. 8](#f0040){ref-type="fig"}a--b). In addition, the result of Co-IP showed that Mybbp1a could also bind to DNMT1 in HCC cell lines ([Fig. 8](#f0040){ref-type="fig"}c). Thus, our study proved that Mybbp1a was able to bind to the CDS site of IGFBP5 and then induce methylation of the CpG site by recruiting DNMT1.Fig. 7Mybbp1a inhibits transcription of IGFBP5 via promoting CpG islands methylation. (a) CpG island methylation level of IGFBP5 in HCC tissue and normal tissue was obtained from TCGA database, and relationship between CpG island methylation level and mRNA level of IGFBP5 was analyzed, (p = .0041, student\'s *t*-test and p = .056, Pearson) (b) CpG sites of IGFBP5 was showed, TSS indicates transcription start site. And the percentages of DNA methylation in specific sites of the IGFBP5 CDS were analyzed by pyrosequencing, (\*p \< .05, student\'s *t*-test) (c--d) The percentages of DNA methylation in specific sites of the IGFBP5 CDS were analyzed by bisulfite sequencing PCR in HCC stable cell line with/without Mybbp1a knockdown, or HCC cell lines treated with 5Aza (0,10 μmol/l) for 48 h. (e) The mRNA level of IGFBP5 was detected under different concentration of 5Aza (0, 10, 20, 40 μmol/l) after 48 h, (\*p \< .05, \*\*\*p \< .0005, student\'s *t*-test). (f) Expression of DNMT1 under different concentration of 5Aza (0, 10, 20, 40 μmol/l) for 48 h was detected.Fig. 7Fig. 8Mybbp1a promoting methylation of CpG island of IGFBP5 through DNMT1. (a--b) Chromatin immunoprecipitation (ChIP) was used to enrichment IGFBP5 CDS region by Mybbp1a or DNMT1 antibody, and PCR was used to verify the efficiency according to the Input. (c) Co-immunoprecipitation assay confirms the protein binding between Mybbp1a and DNMT1. (d) The molecular model depicted the mechanism of Mybbp1a as an oncogene in HCC.Fig. 8

4. Discussion {#s0145}
=============

MYB binding protein 1a (Mybbp1a), a nucleolar transcriptional regulator, was first identified as a binding protein with the MYB proto-oncogene protein \[[@bb0030],[@bb0035]\]. Further studies demonstrated that Mybbp1a played a vital role in response to P53-associated nucleolar stress, the synthesis of ribosomal DNA and amino acids, and the progression of the oxidative phosphorylation respiratory chain \[[@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080],[@bb0120]\]. However, the mechanism of Mybbp1a in tumor initiation and progression was controversial. It was shown that Mybbp1a acted as a tumor suppressor in breast cancer by enhancing p53-associated anoikis and inhibiting the deacetylation activity of H3K18Ac \[[@bb0085],[@bb0125]\]. However, a recent study demonstrated that Mybbp1a enhanced tumor cell proliferation in the early phase of HNSCC and inhibited tumor cell migration and invasion in advanced HNSCC \[[@bb0090]\]. In addition, we found that Mybbp1a was overexpressed in HCC tissues by the Human Protein Atlas database. Based on these, we propose that Mybbp1a may have a special function in the initiation and progression of HCC.

We first demonstrated that Mybbp1a was overexpressed in HCC tissues and that the high expression of Mybbp1a was associated with poor overall and tumor-free survival. Then, loss-of-function experiments showed that suppression of Mybbp1a inhibited the proliferation and migration of HCC cells through G1 phase arrest and suppression of CDC42-mediated cytoskeleton synthesis. To further illustrate this phenomenon, we used transcriptome chip analysis in HCC cells and found that the expression of PI3K/AKT pathway-related genes had significantly changed. As the activation of PI3K/AKT promoted the progression of the cell cycle and cytoskeleton synthesis \[[@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150]\]. And our study validated that suppression of Mybbp1a decreased the expression of pAKT^308^, pAKT^473^, PI3K-P110 and PI3K-P85. In addition, the cell viability and migration capacities of HCC cells with Mybbp1a knockdown were similar to those of HCC cells under the condition of AKT inhibitors. Thus, we proved that Mybbp1a regulated the proliferation and migration of HCC cells via the PI3K-AKT pathway.

To further illustrate the mechanism of Mybbp1a on the activation of the PI3K-AKT pathway, we analyzed the differentially expressed genes on the transcriptome chip and found that the expression of IGFBP5 was significantly increased. IGFBP5, one of the IGF-binding proteins (IGFBP-1 to -6), is a secreted protein that inhibits the IGF1/IGF1R/PI3K/AKT axis through a competitive combination with circulating IGF1 \[[@bb0155]\]. Recent studies reported that IGFBP5 was a tumor suppressor in many solid tumors, including breast cancer \[[@bb0160]\], head and neck cancer \[[@bb0165]\], osteosarcoma \[[@bb0170]\], uterine leiomyoma \[[@bb0175]\], melanoma \[[@bb0180]\], colorectal cancer \[[@bb0185]\], gastrointestinal stromal tumors \[[@bb0190]\] and papillary thyroid carcinoma \[[@bb0195]\]. Based on these data, we hypothesized that the deactivation of the PI3K/AKT pathway under the suppression of Mybbp1a might be due to the increased secretion of IGFBP5.

We first validated that the expression of IGFBP5 was increased both at the mRNA and protein levels under Mybbp1a knockdown. Then, we found that HCC patients with Mybbp1a^High^IGFBP5^Low^ had shorter overall and tumor-free survival than those with Mybbp1a^Low^IGFBP5^High^. CCK-8 and transwell assays showed that the cell viability and migration capacity of HCC cells with Mybbp1a suppression were reversed when suppressing both Mybbp1a and IGFBP5. In addition, we demonstrated that IGFBP5 inhibited the IGF1-mediated activation of the PI3K-AKT pathway in HCC cells. The expression of pIGF1R and pAKT^473^ in HCC cells with shMybbp1a was lower than that of with shMybbp1a + shIGFBP5 or negative controls under the condition of 40 ng/ml IGF1. In summary, we demonstrated that suppression of Mybbp1a inhibited the activation of the IGF1/IGF1R/PI3K/AKT axis through inducing the secretion of IGFBP5.

Thus, we sought to determine how the suppression of Mybbp1a could increase the mRNA level of IGFBP5 in HCC cells, through inhibiting mRNA degradation or promoting mRNA synthesis. First, we thought that suppression of Mybbp1a might induce changes in the expression of IGFBP5-related miRNAs. miRNAs are a class of highly conserved short RNAs of 21--23 nucleotides that induce the degradation of mRNAs by binding to the 3′untranslated region (3′UTR) of their targeted mRNAs \[[@bb0200],[@bb0205]\]. Then, we performed miRNA sequencing in HCC cells with shMybbp1a or the negative control and found five candidate miRNAs (miR-3187-3p, miR-210-5p, miR-671-5p, miR-1260b and miR-128-1-5p). However, the mimics of these miRNAs could not significantly decrease the mRNA level of IGFBP5 in HCC cells with shMybbp1a. Then, we tried to find a breakthrough from DNA methylation modification, which is the major epigenetic modification that involves alterations of the chromatin structure. Increasing evidence demonstrated that aberrant methylation of CpG islands in the tumor suppressor gene led to transcriptional silencing in cancer \[[@bb0210],[@bb0215]\]. Based on these data, we analyzed the sequence of IGFBP5, including the promoter region, CDS site, 5′ UTR Exons, 3′ UTR Exons and Introns, and found that there were CpG islands in the CDS site of IGFBP5. Then, the results of Bisulfite Sequencing and Pyrosequencing showed that the methylation levels of specific sites significantly decreased under Mybbp1a suppression. In addition, we found that Mybbp1a was able to specifically bind to DNMT1 and the CDS site of IGFBP5. Thus, we demonstrated that Mybbp1a inhibited the secretion of IGFBP5 by increasing the methylation level of CpG islands of the CDS site by recruiting DNMT1.

In conclusion, our study found that Mybbp1a suppressed the transcription of IGFBP5 through the DNMT1-mediated hyper-methylation level of CpG islands in the IGFBP5 CDS site. This biological process led to a loss of the secretion of IGFBP5, which improved the combinative efficiency between IGF1 and IGF1R. Then, phosphorylation of IGF1R induced the activation of the PI3K-AKT pathway, which increased the proliferation rate and migration capacity of HCC cells ([Fig. 8](#f0040){ref-type="fig"}d). Though the most of the published studies reported the negative role of Mybbp1a in various cancer types, however, high heterogeneity of tumors from different tissue sources indicated that Mybbp1a may act as different role during progression of different solid tumors. Therefore, our findings raised an intriguing hypothesis that Mybbp1a might serve as a "switch" to regulate the secretion of IGFBP5 to cater to the needs of HCC progression.

However, our study only demonstrated Mybbp1a could affect the methylation of CpG island in CDS site of IGFBP5, further studies were needed to prove whether Mybbp1a could regulate other CpG islands methylation of IGFBP5 or regulate the transcription of IGFBP5 by other pathways?

The following are the supplementary data related to this article.Supplementary Fig. 1Showed the results of Kaplan-meier analysis between Mybbp1a high-expression and low-expression, the follow-up data was supplied by TCGA database, (p = .00157, Log Rank (Mantel-Cox)).Supplementary Fig. 1Supplementary Fig. 2Showed the results of CCK-8 assay in HCC cells with shMybbp1a or negative control (NC), and the results of 72 h were used for statistical analysis, (\*\*\*P \< .0005, one-way ANOVA).Supplementary Fig. 2Supplementary Fig. 3showed the results of colony formation assay in HCC cells with shMybbp1a-2 or negative control (NC).Supplementary Fig. 3Supplementary Fig. 4showed the results of Flow cycle analysis in HCC cells with shMybbp1a-2 or negative control (NC), and the result was statistical analyzed, (\*p \< .05, student\'s *t*-test).Supplementary Fig. 4Supplementary Fig. 5showed the expression change of G1 phase associated proteins in HCC cells with shMybbp1a-2 or negative control (NC).Supplementary Fig. 5Supplementary Fig. 6Showed the results of transwell assay and wound healing assay in HCC cells with shMybbp1a-2 or negative control (NC), and the result was statistical analyzed, (\*p \< .05, \*\*p \< .005, student\'s *t*-test).Supplementary Fig. 6Supplementary Fig. 7Cell G1 phase associated proteins were detected under different concentration of MK2206(0, 5 μmol/l), pAKT473 was used to verify the efficiency of the drug.Supplementary Fig. 7Supplementary Fig. 8Cell cytoskeleton was detected under different concentration of MK2206(0, 5 μmol/l) (scale bar = 1um), Cytoskeletal synthesis protein CDC42 was detected.Supplementary Fig. 8Supplementary Fig. 9Showed the results of Kaplan-meier analysis among Mybbp1a^High^IGFBP5^Low^, Mybbp1a^Low^IGFBP5^High^, Mybbp1a^High^IGFBP5^High^ and Mybbp1a^Low^IGFBP5^Low^, (p = .805, p = .497, p = .635 and p = .307 respectively, Log Rank (Mantel-Cox)).Supplementary Fig. 9Supplementary Fig. 10(a) The heat map and candidate miRNAs from the miRNA sequencing were shown, and complementary pairing sequence between miRNAs 3′UTR and IGFBP5 mRNA were obtained from TargetScan database. (b) The mRNA level of IGFBP5 under treatment of miRNAs mimics was detected and quantified.Supplementary Fig. 10Supplementary Fig. 11The CpG islands of IGFBP5 promote site and CDS site were analyzed by Methprimer.Supplementary Fig. 11Supplementary tablesImage 1
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